A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Latest Information Update: 04 Nov 2021
At a glance
- Drugs IMR-261 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Complexa
- 24 Aug 2020 Status changed from recruiting to discontinued due to LOE.
- 13 Aug 2019 Status changed from not yet recruiting to recruiting.
- 13 Aug 2019 New trial record